Deliang Lv, W. Tan, Jian Xu, Hui Yang, Jun-luan Mo, Yu-mei Zhu, Xiongshun Liang, X. Che, Qingfang Wu
{"title":"Effect of first-line antituberculous treatment on vitamin D level in patients with pulmonary tuberculosis","authors":"Deliang Lv, W. Tan, Jian Xu, Hui Yang, Jun-luan Mo, Yu-mei Zhu, Xiongshun Liang, X. Che, Qingfang Wu","doi":"10.3760/CMA.J.ISSN.1674-635X.2019.02.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the effect of first-line anti-tuberculosis treatment on vitamin D level in patients with pulmonary tuberculosis, and to master the changes of vitamin D level in the course of treatment, so as to provide a scientific basis for tuberculosis and nutrition health education in Shenzhen. \n \n \nMethods \nA total of 100 patients diagnosed as smear-positive pulmonary tuberculosis and receiving initial treatment in 2016 were enrolled and all the patients were treated with the standardized short-course chemotherapy regimens. The blood samples were extracted before treatment and at the ends of intensive and continuation phase. The 25-hydroxyvitamin D[25-(OH)D] concentrations were determined by chemiluminescence (CLIA)at each time point. The change of 25-(OH)D concentrations during anti-tuberculosis treatment was analyzed and the differences of vitamin D levels between different time points were identified. \n \n \nResults \n79(79.0%), 94(94.0%) and 96(96.0%)patients were found vitamin D deficiency before treatment and at the end of the intensive and continuation phases respectively, which showed an upward trend(χ2=15.543, P<0.001)and the 25-(OH)D concentrations were (15.74±6.54)ng/ml, (12.56±5.15)ng/ml, (11.51±4.28)ng/ml, respectively. During the whole course of treatment, the 25-(OH)D concentration decreased by 26.9% or (4.23±6.75)ng/ml(t=6.257, P<0.001), wherein it decreased (3.18±5.24)ng/ml in intensive phase (t=6.069, P<0.001) and (1.05±4.86)ng/ml in continuation phase (t=2.154, P=0.034). The former had a greater decreased value (t=2.836, P=0.006). There were 77 (77.0%) and 55 (55.0%) patients with 25-(OH)D concentration reduction in intensive and continuation phases respectively(χ2=9.680, P=0.003), of which 41 patients (41.0%) continued to decline. \n \n \nConclusion \nOnce anti-tuberculosis treatment is conducted, the vitamin D level will decrease rapidly in the intensive phase and continue decreasing throughout the course of treatment, which leads to a general lack of vitamin D in patients with primary pulmonary tuberculosis. First-line anti-tuberculosis drugs may be the main cause for vitamin D level reduction. Therefore, it is necessary for clinicians to strengthen vitamin D health education for each patient throughout the treatment period, especially for those at high risk of vitamin D deficiency who should be recommended adjuvant vitamin D supplementation therapy. \n \n \nKey words: \nPulmonary tuberculosis; Vitamin D deficiency; 25-hydroxyvitamin D; Anti-tuberculosis drug","PeriodicalId":9877,"journal":{"name":"中华临床营养杂志","volume":"27 1","pages":"90-95"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华临床营养杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-635X.2019.02.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To explore the effect of first-line anti-tuberculosis treatment on vitamin D level in patients with pulmonary tuberculosis, and to master the changes of vitamin D level in the course of treatment, so as to provide a scientific basis for tuberculosis and nutrition health education in Shenzhen.
Methods
A total of 100 patients diagnosed as smear-positive pulmonary tuberculosis and receiving initial treatment in 2016 were enrolled and all the patients were treated with the standardized short-course chemotherapy regimens. The blood samples were extracted before treatment and at the ends of intensive and continuation phase. The 25-hydroxyvitamin D[25-(OH)D] concentrations were determined by chemiluminescence (CLIA)at each time point. The change of 25-(OH)D concentrations during anti-tuberculosis treatment was analyzed and the differences of vitamin D levels between different time points were identified.
Results
79(79.0%), 94(94.0%) and 96(96.0%)patients were found vitamin D deficiency before treatment and at the end of the intensive and continuation phases respectively, which showed an upward trend(χ2=15.543, P<0.001)and the 25-(OH)D concentrations were (15.74±6.54)ng/ml, (12.56±5.15)ng/ml, (11.51±4.28)ng/ml, respectively. During the whole course of treatment, the 25-(OH)D concentration decreased by 26.9% or (4.23±6.75)ng/ml(t=6.257, P<0.001), wherein it decreased (3.18±5.24)ng/ml in intensive phase (t=6.069, P<0.001) and (1.05±4.86)ng/ml in continuation phase (t=2.154, P=0.034). The former had a greater decreased value (t=2.836, P=0.006). There were 77 (77.0%) and 55 (55.0%) patients with 25-(OH)D concentration reduction in intensive and continuation phases respectively(χ2=9.680, P=0.003), of which 41 patients (41.0%) continued to decline.
Conclusion
Once anti-tuberculosis treatment is conducted, the vitamin D level will decrease rapidly in the intensive phase and continue decreasing throughout the course of treatment, which leads to a general lack of vitamin D in patients with primary pulmonary tuberculosis. First-line anti-tuberculosis drugs may be the main cause for vitamin D level reduction. Therefore, it is necessary for clinicians to strengthen vitamin D health education for each patient throughout the treatment period, especially for those at high risk of vitamin D deficiency who should be recommended adjuvant vitamin D supplementation therapy.
Key words:
Pulmonary tuberculosis; Vitamin D deficiency; 25-hydroxyvitamin D; Anti-tuberculosis drug
期刊介绍:
The Chinese Journal of Clinical Nutrition was founded in 1993. It is the first professional academic journal (bimonthly) in my country co-sponsored by the Chinese Medical Association and the Chinese Academy of Medical Sciences to disseminate information on clinical nutrition support, nutrient metabolism, the impact of nutrition support on outcomes and "cost-effectiveness", as well as translational medicine and nutrition research. It is also a professional journal of the Chinese Medical Association's Parenteral and Enteral Nutrition Branch.
The purpose of the Chinese Journal of Clinical Nutrition is to promote the rapid dissemination of knowledge on nutrient metabolism and the rational application of parenteral and enteral nutrition, focusing on the combination of multidisciplinary and multi-regional field investigations and clinical research. It mainly reports on nutritional risk screening related to the indications of parenteral and enteral nutrition support, "cost-effectiveness" research on nutritional drugs, consensus on clinical nutrition, guidelines, expert reviews, randomized controlled studies, cohort studies, glycoprotein and other nutrient metabolism research, systematic evaluation of clinical research, evidence-based case reports, special reviews, case reports and clinical experience exchanges, etc., and has a special column on new technologies related to the field of clinical nutrition and their clinical applications.